SCHEMBL652004

SCHEMBL652004

O=C1NC(=Nc2ccc3cn[nH]c3c2)SC1=Cc1cnc(NCCCN2CCOCC2)s1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.42
KMT2A Q03164 4/20 0.42
MEN1 O00255 3/20 0.42
PKM P14618 2/20 0.42
MAPK1 P28482 2/20 0.42
RXFP1 Q9HBX9 1/20 0.42
KDM4E B2RXH2 1/20 0.36
GAA P10253 1/20 0.36
APOBEC3G Q9HC16 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
RAB9A P51151 2/20 0.35
POLB P06746 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
USP2 O75604 1/20 0.35
ALDH1A1 P00352 1/20 0.35
RECQL P46063 1/20 0.35
BLM P54132 1/20 0.35
SAE1 Q9UBE0 1/20 0.35
UBA2 Q9UBT2 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL652003 1.00 MAPT (0.42) MAPTKMT2AMEN1PKMMAPK1
SCHEMBL10227930 1.00 MAPT (0.42) MAPTKMT2AMEN1PKMMAPK1
SCHEMBL10227032 0.93 MAPT (0.36) MAPTKMT2AMEN1PKMMAPK1
SCHEMBL654039 0.93 MAPT (0.36) MAPTKMT2AMEN1PKMMAPK1
SCHEMBL654040 0.93 MAPT (0.36) MAPTKMT2AMEN1PKMMAPK1
SCHEMBL650789 0.85 KMT2A (0.37) MAPTKMT2AMEN1MAPK1APOBEC3G
SCHEMBL650790 0.85 KMT2A (0.37) MAPTKMT2AMEN1MAPK1APOBEC3G
SCHEMBL10227026 0.85 KMT2A (0.37) MAPTKMT2AMEN1MAPK1APOBEC3G
SCHEMBL651347 0.84 KMT2A (0.37) MAPTKMT2AMEN1MAPK1APOBEC3G
SCHEMBL10227917 0.84 KMT2A (0.37) MAPTKMT2AMEN1MAPK1APOBEC3G

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2423204-A1 THIAZOLIDINONE DERIVATIVE SBI Biotech Co., Ltd. (JP) 2012-02-29 EP disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE CDC7, CDK17, CDCA2 MAPT 3657/4885KMT2A 3437/4885MEN1 1406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.